BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//DataCutoff//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:DataCutoff · $1177.HK readouts
X-WR-CALDESC:Clinical-trial primary completion dates from ClinicalTrials.go
 v\, refreshed nightly by DataCutoff. Not investment advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04344158-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:~AK105 Injection readout (P3) · Chia Tai Tianqing Pharmaceutical G
 roup Co.\, Ltd. $1177.HK
DESCRIPTION:A Phase III Clinical Trial of AK105 Injection Combined With Anl
 otinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced H
 epatocellular Carcinoma (HCC)\n\nPrimary completion date: 2026-12 (estimat
 ed) — month only\, shown on the 1st\nOriginally planned: 2024-06-30 (+29
 .0 months)\nPhase 3 · Oncology · Advanced Hepatocellular Carcinoma (HCC)
 \nEnrollment: 648 · Sites: 81\n\nPrimary completion = last participant's 
 primary-endpoint data collected\; topline results usually follow weeks to 
 months later. Sponsor-reported\, often an estimate. Not investment advice.
 \n\nhttps://datacutoff.com/radar.html?nct=NCT04344158\nhttps://clinicaltri
 als.gov/study/NCT04344158
URL:https://datacutoff.com/radar.html?nct=NCT04344158
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05780567-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:~TQB3616 capsules\, Letrozole\, Anastrozole\, Tamoxif… readout (P
 3) · Chia Tai Tianqing Pharmaceutical Group Co.\, Ltd. $1177.HK
DESCRIPTION:Clinical Study on Adjuvant Therapy of TQB3616 Combined With End
 ocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Pa
 tients With Breast Cancer\n\nPrimary completion date: 2026-12 (estimated) 
 — month only\, shown on the 1st\nPhase 3 · Oncology · Breast Cancer\nE
 nrollment: 1946 · Sites: 3\n\nPrimary completion = last participant's pri
 mary-endpoint data collected\; topline results usually follow weeks to mon
 ths later. Sponsor-reported\, often an estimate. Not investment advice.\n\
 nhttps://datacutoff.com/radar.html?nct=NCT05780567\nhttps://clinicaltrials
 .gov/study/NCT05780567
URL:https://datacutoff.com/radar.html?nct=NCT05780567
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05987358-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:~TQB3454 tablets readout (P3) · Chia Tai Tianqing Pharmaceutical G
 roup Co.\, Ltd. $1177.HK
DESCRIPTION:A Clinical Study of TQB3454 Tablets in the Treatment of Advance
 d Biliary Carcinoma.\n\nPrimary completion date: 2026-12 (estimated) — m
 onth only\, shown on the 1st\nPhase 3 · Oncology · Biliary Carcinoma\nEn
 rollment: 165 · Sites: 6\n\nPrimary completion = last participant's prima
 ry-endpoint data collected\; topline results usually follow weeks to month
 s later. Sponsor-reported\, often an estimate. Not investment advice.\n\nh
 ttps://datacutoff.com/radar.html?nct=NCT05987358\nhttps://clinicaltrials.g
 ov/study/NCT05987358
URL:https://datacutoff.com/radar.html?nct=NCT05987358
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06707883-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:~TQC2731 injection readout (P2) · Shanghai Chia Tai Tianqing Pharm
 aceutical Technology Development Co.\, Ltd. $1177.HK
DESCRIPTION:A Clinical Study of TQC2731 Injection in Patients With Moderate
  to Severe Chronic Obstructive Pulmonary Disease\n\nPrimary completion dat
 e: 2026-12 (estimated) — month only\, shown on the 1st\nPhase 2 · Respi
 ratory · Chronic Obstructive Pulmonary Disease\nEnrollment: 258 · Sites:
  60\n\nPrimary completion = last participant's primary-endpoint data colle
 cted\; topline results usually follow weeks to months later. Sponsor-repor
 ted\, often an estimate. Not investment advice.\n\nhttps://datacutoff.com/
 radar.html?nct=NCT06707883\nhttps://clinicaltrials.gov/study/NCT06707883
URL:https://datacutoff.com/radar.html?nct=NCT06707883
CATEGORIES:Respiratory,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06859931-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:~TQB3702 Tablets readout (P2) · Chia Tai Tianqing Pharmaceutical G
 roup Co.\, Ltd. $1177.HK
DESCRIPTION:Clinical Trial of TQB3702 Tablets in Subjects With Systemic Lup
 us Erythematosus (SLE)\n\nPrimary completion date: 2026-12 (estimated) —
  month only\, shown on the 1st\nPhase 2 · Immuno · Systemic Lupus Erythe
 matosus\nEnrollment: 120 · Sites: 37\n\nPrimary completion = last partici
 pant's primary-endpoint data collected\; topline results usually follow we
 eks to months later. Sponsor-reported\, often an estimate. Not investment 
 advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT06859931\nhttps://clin
 icaltrials.gov/study/NCT06859931
URL:https://datacutoff.com/radar.html?nct=NCT06859931
CATEGORIES:Immuno,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06561607-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:~TQB2102 for Injection readout (P3) · Chia Tai Tianqing Pharmaceut
 ical Group Co.\, Ltd. $1177.HK
DESCRIPTION:A Clinical Trial of TQB2102 for Injection in the Treatment of H
 ER2 Low-Expressing Recurrent/Metastatic Breast Cancer\n\nPrimary completio
 n date: 2027-01 (estimated) — month only\, shown on the 1st\nPhase 3 · 
 Oncology · Breast Cancer\nEnrollment: 542 · Sites: 34\n\nPrimary complet
 ion = last participant's primary-endpoint data collected\; topline results
  usually follow weeks to months later. Sponsor-reported\, often an estimat
 e. Not investment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT0656
 1607\nhttps://clinicaltrials.gov/study/NCT06561607
URL:https://datacutoff.com/radar.html?nct=NCT06561607
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06860971-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20270101
DTEND;VALUE=DATE:20270102
SUMMARY:~AL2846 Capsules readout (P3) · Chia Tai Tianqing Pharmaceutical G
 roup Co.\, Ltd. $1177.HK
DESCRIPTION:A Study of AL2846 Capsule Versus Placebo in the Treatment of Ad
 vanced Radioiodine-Refractory Differentiated Thyroid Carcinoma\n\nPrimary 
 completion date: 2027-01 (estimated) — month only\, shown on the 1st\nPh
 ase 3 · Oncology · Thyroid Cancer\nEnrollment: 144 · Sites: 35\n\nPrima
 ry completion = last participant's primary-endpoint data collected\; topli
 ne results usually follow weeks to months later. Sponsor-reported\, often 
 an estimate. Not investment advice.\n\nhttps://datacutoff.com/radar.html?n
 ct=NCT06860971\nhttps://clinicaltrials.gov/study/NCT06860971
URL:https://datacutoff.com/radar.html?nct=NCT06860971
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07464587-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20270201
DTEND;VALUE=DATE:20270202
SUMMARY:~TQC3721 Suspension for Inhalation readout (P3) · Chia Tai Tianqin
 g Pharmaceutical Group Co.\, Ltd. $1177.HK
DESCRIPTION:Evaluation of the Inhaled TQC3721 Suspension in Patients With M
 oderate-to-Severe Chronic Obstructive Pulmonary Disease\n\nPrimary complet
 ion date: 2027-02 (estimated) — month only\, shown on the 1st\nPhase 3 
 · Respiratory · Chronic Obstructive Pulmonary Disease\nEnrollment: 800 
 · Sites: 54\n\nPrimary completion = last participant's primary-endpoint d
 ata collected\; topline results usually follow weeks to months later. Spon
 sor-reported\, often an estimate. Not investment advice.\n\nhttps://datacu
 toff.com/radar.html?nct=NCT07464587\nhttps://clinicaltrials.gov/study/NCT0
 7464587
URL:https://datacutoff.com/radar.html?nct=NCT07464587
CATEGORIES:Respiratory,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06900920-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:~TQB3473 Tablets readout (P3) · Chia Tai Tianqing Pharmaceutical G
 roup Co.\, Ltd. $1177.HK
DESCRIPTION:A Study of TQB3473 Tablets Compared to Placebo in the Treatment
  of Adult Primary Immune Thrombocytopenia\n\nPrimary completion date: 2027
 -03 (estimated) — month only\, shown on the 1st\nPhase 3 · Cardio-Met 
 · Primary Immune Thrombocytopenia\nEnrollment: 199 · Sites: 53\n\nPrimar
 y completion = last participant's primary-endpoint data collected\; toplin
 e results usually follow weeks to months later. Sponsor-reported\, often a
 n estimate. Not investment advice.\n\nhttps://datacutoff.com/radar.html?nc
 t=NCT06900920\nhttps://clinicaltrials.gov/study/NCT06900920
URL:https://datacutoff.com/radar.html?nct=NCT06900920
CATEGORIES:Cardio-Met,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07107256-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:~TQC2731 injection readout (P3) · Shanghai Chia Tai Tianqing Pharm
 aceutical Technology Development Co.\, Ltd. $1177.HK
DESCRIPTION:Clinical Trial of TQC2731 Injection in Patients With Chronic Si
 nusitis and Nasal Polyps\n\nPrimary completion date: 2027-03 (estimated) 
 — month only\, shown on the 1st\nPhase 3 · Other · Chronic Rhinosinusi
 tis With Nasal Polyps (CRSwNP)\nEnrollment: 246 · Sites: 60\n\nPrimary co
 mpletion = last participant's primary-endpoint data collected\; topline re
 sults usually follow weeks to months later. Sponsor-reported\, often an es
 timate. Not investment advice.\n\nhttps://datacutoff.com/radar.html?nct=NC
 T07107256\nhttps://clinicaltrials.gov/study/NCT07107256
URL:https://datacutoff.com/radar.html?nct=NCT07107256
CATEGORIES:Other,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07147946-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:~TQC3721 Suspension for inhalation readout (P3) · Chia Tai Tianqin
 g Pharmaceutical Group Co.\, Ltd. $1177.HK
DESCRIPTION:Evaluation of the Clinical Trial of Inhaled TQC3721 Suspension 
 in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease\
 n\nPrimary completion date: 2027-03 (estimated) — month only\, shown on 
 the 1st\nPhase 3 · Respiratory · Chronic Obstructive Pulmonary Disease\n
 Enrollment: 666 · Sites: 76\n\nPrimary completion = last participant's pr
 imary-endpoint data collected\; topline results usually follow weeks to mo
 nths later. Sponsor-reported\, often an estimate. Not investment advice.\n
 \nhttps://datacutoff.com/radar.html?nct=NCT07147946\nhttps://clinicaltrial
 s.gov/study/NCT07147946
URL:https://datacutoff.com/radar.html?nct=NCT07147946
CATEGORIES:Respiratory,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06789289-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20270317
DTEND;VALUE=DATE:20270318
SUMMARY:TQC2938 injection readout (P2) · Chia Tai Tianqing Pharmaceutical 
 Group Nanjing Shunxin Pharmaceutical Co.\, Ltd. $1177.HK
DESCRIPTION:A Clinical Study to Evaluate the Efficacy and Safety of TQC2938
  in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
 \n\nPrimary completion date: 2027-03-17 (estimated)\nOriginally planned: 2
 027-12 (-8.5 months)\nPhase 2 · Respiratory · Chronic Obstructive Pulmon
 ary Disease\nEnrollment: 256 · Sites: 40\n\nPrimary completion = last par
 ticipant's primary-endpoint data collected\; topline results usually follo
 w weeks to months later. Sponsor-reported\, often an estimate. Not investm
 ent advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT06789289\nhttps://
 clinicaltrials.gov/study/NCT06789289
URL:https://datacutoff.com/radar.html?nct=NCT06789289
CATEGORIES:Respiratory,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06351150-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:~Angiotensin II Injection readout (P3) · Chia Tai Tianqing Pharmac
 eutical Group Co.\, Ltd. $1177.HK
DESCRIPTION:Efficacy and Safety of Angiotensin II Injection Versus Placebo 
 in Patients With Refractory Distributed Shock\n\nPrimary completion date: 
 2027-06 (estimated) — month only\, shown on the 1st\nPhase 3 · Other ·
  Vasodilatory Shock\nEnrollment: 214 · Sites: 42\n\nPrimary completion = 
 last participant's primary-endpoint data collected\; topline results usual
 ly follow weeks to months later. Sponsor-reported\, often an estimate. Not
  investment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT06351150\n
 https://clinicaltrials.gov/study/NCT06351150
URL:https://datacutoff.com/radar.html?nct=NCT06351150
CATEGORIES:Other,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07512596-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20270701
DTEND;VALUE=DATE:20270702
SUMMARY:~TQD3524 readout (P2) · Chia Tai Tianqing Pharmaceutical Group Co.
 \, Ltd. $1177.HK
DESCRIPTION:Study on the Safety and Efficacy of Polymyxin E2 Methanesulfona
 te for Injection in the Treatment of Hospital-Acquired Bacterial Pneumonia
 /Ventilator-Associated Bacterial Pneumonia…\n\nPrimary completion date: 
 2027-07 (estimated) — month only\, shown on the 1st\nPhase 2 · Infectio
 us · Hospital-acquired Bacterial Pneumonia/Ventilator-associated…\nEnro
 llment: 48 · Sites: 27\n\nPrimary completion = last participant's primary
 -endpoint data collected\; topline results usually follow weeks to months 
 later. Sponsor-reported\, often an estimate. Not investment advice.\n\nhtt
 ps://datacutoff.com/radar.html?nct=NCT07512596\nhttps://clinicaltrials.gov
 /study/NCT07512596
URL:https://datacutoff.com/radar.html?nct=NCT07512596
CATEGORIES:Infectious,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06962267-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:~TQB2916 Injection readout (P2) · Chia Tai Tianqing Pharmaceutical
  Group Nanjing Shunxin Pharmaceutical Co.\, Ltd. $1177.HK
DESCRIPTION:A Clinical Study on the First-line Treatment of Metastatic Panc
 reatic Cancer With TQB2916 Injection Combined With Gemcitabine Hydrochlori
 de for Injection and Paclitaxel for Inject…\n\nPrimary completion date: 
 2027-08 (estimated) — month only\, shown on the 1st\nPhase 2 · Oncology
  · Pancreatic Cancer\nEnrollment: 50 · Sites: 1\n\nPrimary completion = 
 last participant's primary-endpoint data collected\; topline results usual
 ly follow weeks to months later. Sponsor-reported\, often an estimate. Not
  investment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT06962267\n
 https://clinicaltrials.gov/study/NCT06962267
URL:https://datacutoff.com/radar.html?nct=NCT06962267
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07406035-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:~TQH3906 Capsule readout (P2) · Chia Tai Tianqing Pharmaceutical G
 roup Nanjing Shunxin Pharmaceutical Co.\, Ltd. $1177.HK
DESCRIPTION:A Clinical Trial of TQH3906 Capsules in the Treatment of Active
  Psoriatic Arthritis\n\nPrimary completion date: 2027-08 (estimated) — m
 onth only\, shown on the 1st\nPhase 2 · Immuno · Psoriatic Arthritis\nEn
 rollment: 156 · Sites: 44\n\nPrimary completion = last participant's prim
 ary-endpoint data collected\; topline results usually follow weeks to mont
 hs later. Sponsor-reported\, often an estimate. Not investment advice.\n\n
 https://datacutoff.com/radar.html?nct=NCT07406035\nhttps://clinicaltrials.
 gov/study/NCT07406035
URL:https://datacutoff.com/radar.html?nct=NCT07406035
CATEGORIES:Immuno,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07483684-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20270801
DTEND;VALUE=DATE:20270802
SUMMARY:~TQB2102 Injection readout (P3) · Chia Tai Tianqing Pharmaceutical
  Group Nanjing Shunxin Pharmaceutical Co.\, Ltd. $1177.HK
DESCRIPTION:A Clinical Study to Evaluate Injection TQB2102 for the Treatmen
 t of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed Af
 ter Treatment With Oxaliplatin\, Irinotecan…\n\nPrimary completion date:
  2027-08 (estimated) — month only\, shown on the 1st\nPhase 3 · Oncolog
 y · HER2 IHC3+ Advanced Colorectal Cancer\nEnrollment: 142 · Sites: 48\n
 \nPrimary completion = last participant's primary-endpoint data collected\
 ; topline results usually follow weeks to months later. Sponsor-reported\,
  often an estimate. Not investment advice.\n\nhttps://datacutoff.com/radar
 .html?nct=NCT07483684\nhttps://clinicaltrials.gov/study/NCT07483684
URL:https://datacutoff.com/radar.html?nct=NCT07483684
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07878091-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20270815
DTEND;VALUE=DATE:20270816
SUMMARY:Kylo 0603 Capsule 8mg readout (P2) · Shanghai Chia Tai Tianqing Ph
 armaceutical Technology Development Co.\, Ltd. $1177.HK
DESCRIPTION:A Phase 2a Study of Kylo-0603 Capsule in Participants With Meta
 bolic Dysfunction Associated Steatotic Liver Disease (MASLD)\n\nPrimary co
 mpletion date: 2027-08-15 (estimated)\nPhase 2 · Cardio-Met · Metabolic 
 Dysfunction-Associated Steatoic Liver Disease\nEnrollment: 120 · Sites: 1
 \n\nPrimary completion = last participant's primary-endpoint data collecte
 d\; topline results usually follow weeks to months later. Sponsor-reported
 \, often an estimate. Not investment advice.\n\nhttps://datacutoff.com/rad
 ar.html?nct=NCT07878091\nhttps://clinicaltrials.gov/study/NCT07878091
URL:https://datacutoff.com/radar.html?nct=NCT07878091
CATEGORIES:Cardio-Met,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07043725-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:~TQB2102 for injection readout (P3) · Chia Tai Tianqing Pharmaceut
 ical Group Nanjing Shunxin Pharmaceutical Co.\, Ltd. $1177.HK
DESCRIPTION:A Clinical Study of Neoadjuvant Treatment With TQB2102 for Inje
 ction for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast 
 Cancer\n\nPrimary completion date: 2027-09 (estimated) — month only\, sh
 own on the 1st\nPhase 3 · Oncology · HER2-positive Breast Cancer\nEnroll
 ment: 544 · Sites: 77\n\nPrimary completion = last participant's primary-
 endpoint data collected\; topline results usually follow weeks to months l
 ater. Sponsor-reported\, often an estimate. Not investment advice.\n\nhttp
 s://datacutoff.com/radar.html?nct=NCT07043725\nhttps://clinicaltrials.gov/
 study/NCT07043725
URL:https://datacutoff.com/radar.html?nct=NCT07043725
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07083739-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:~TQB3473 Tablets readout (P2) · Chia Tai Tianqing Pharmaceutical G
 roup Co.\, Ltd. $1177.HK
DESCRIPTION:A Study on the Safety and Efficacy of TQB3473 Tablets in the Tr
 eatment of Persistent or Chronic Primary Immune Thrombocytopenia (ITP) in 
 Adults\n\nPrimary completion date: 2027-09 (estimated) — month only\, sh
 own on the 1st\nPhase 2 · Cardio-Met · Primary Immune Thrombocytopenia\n
 Enrollment: 320 · Sites: 51\n\nPrimary completion = last participant's pr
 imary-endpoint data collected\; topline results usually follow weeks to mo
 nths later. Sponsor-reported\, often an estimate. Not investment advice.\n
 \nhttps://datacutoff.com/radar.html?nct=NCT07083739\nhttps://clinicaltrial
 s.gov/study/NCT07083739
URL:https://datacutoff.com/radar.html?nct=NCT07083739
CATEGORIES:Cardio-Met,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07724366-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20270901
DTEND;VALUE=DATE:20270902
SUMMARY:~TQH3906 capsules readout (P3) · Chia Tai Tianqing Pharmaceutical 
 Group Nanjing Shunxin Pharmaceutical Co.\, Ltd. $1177.HK
DESCRIPTION:A Clinical Trial of TQH3906 Capsules in Adult Patients With Mod
 erate to Severe Plaque Psoriasis\n\nPrimary completion date: 2027-09 (esti
 mated) — month only\, shown on the 1st\nPhase 3 · Immuno · Psoriasis\n
 Enrollment: 400 · Sites: 45\n\nPrimary completion = last participant's pr
 imary-endpoint data collected\; topline results usually follow weeks to mo
 nths later. Sponsor-reported\, often an estimate. Not investment advice.\n
 \nhttps://datacutoff.com/radar.html?nct=NCT07724366\nhttps://clinicaltrial
 s.gov/study/NCT07724366
URL:https://datacutoff.com/radar.html?nct=NCT07724366
CATEGORIES:Immuno,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06300320-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:~TQ05105 tablets readout (P2) · Chia Tai Tianqing Pharmaceutical G
 roup Co.\, Ltd. $1177.HK
DESCRIPTION:A Clinical Trial of TQ05105 Tablets in the Treatment of Chronic
  Graft-versus-host Disease\n\nPrimary completion date: 2027-11 (estimated)
  — month only\, shown on the 1st\nOriginally planned: 2025-10 (+25.0 mon
 ths)\nPhase 2 · Respiratory · Chronic Graft Versus Host Disease\nEnrollm
 ent: 65 · Sites: 12\n\nPrimary completion = last participant's primary-en
 dpoint data collected\; topline results usually follow weeks to months lat
 er. Sponsor-reported\, often an estimate. Not investment advice.\n\nhttps:
 //datacutoff.com/radar.html?nct=NCT06300320\nhttps://clinicaltrials.gov/st
 udy/NCT06300320
URL:https://datacutoff.com/radar.html?nct=NCT06300320
CATEGORIES:Respiratory,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07509892-pcd@datacutoff.com
DTSTAMP:20261118T192902Z
DTSTART;VALUE=DATE:20271101
DTEND;VALUE=DATE:20271102
SUMMARY:~TQH3906 capsule readout (P2) · Chia Tai Tianqing Pharmaceutical G
 roup Co.\, Ltd. $1177.HK
DESCRIPTION:A Clinical Trial on the Efficacy and Safety of TQH3906 in the T
 reatment of Systemic Lupus Erythematosus\n\nPrimary completion date: 2027-
 11 (estimated) — month only\, shown on the 1st\nPhase 2 · Immuno · Sys
 temic Lupus Erythematosus\nEnrollment: 198 · Sites: 35\n\nPrimary complet
 ion = last participant's primary-endpoint data collected\; topline results
  usually follow weeks to months later. Sponsor-reported\, often an estimat
 e. Not investment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT0750
 9892\nhttps://clinicaltrials.gov/study/NCT07509892
URL:https://datacutoff.com/radar.html?nct=NCT07509892
CATEGORIES:Immuno,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
